During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
|Videos|September 12, 2017
- Non-Small Cell Lung Cancer
- Volume 1
- Issue 1
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
Corey J. Langer, MD, Perelman Center for Advanced Medicine; Hospital of the University of Pennsylvania, discusses remaining challenges in the treatment of patients with non-driver non-small cell lung cancer.
Advertisement
Articles in this issue
about 9 years ago
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLCabout 9 years ago
Emerging Treatment Strategies in Nonsquamous NSCLCabout 9 years ago
Nonbiomarker NSCLC Population a Challenging Obstacle, Expert Saysabout 9 years ago
Dr. Bazhenova on the Prevalence of Patients With Non-Driver NSCLCAdvertisement
Related to this article
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
5